Health ❯ Healthcare

Clinical Trials

Phase 3 Trials Drug Development Drug Efficacy Patient Outcomes Phase III Trials Randomized Controlled Trials Research Studies Cancer Research Efficacy Studies Cancer Treatment

FDA Clears Wegovy Weight-Loss Pill, First Oral GLP-1 for Obesity, With January U.S. Launch

The first oral option in this class could broaden uptake by removing injections as a barrier.

Edgewise Reports Favorable Interim Safety in Phase 2 HCM Trial of EDG-7500

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

FDA Approves Aqvesme for Thalassemia Anemia, First U.S. Therapy for Both Patient Groups

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

AstraZeneca Withdraws Andexxa From U.S. Market After FDA Says Risks Outweigh Benefits

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

Largest Blood-Test Study Finds Alzheimer’s Changes Common in Older Adults

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

DBV Peanut Allergy Patch Succeeds in Pivotal Phase 3, Setting Up 2026 FDA Filing

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

FDA Clears First New Oral Gonorrhea Antibiotics in Over 30 Years